Plan les Ouates, Switzerland

Selexis S.a.


USPTO Granted Patents = 6



Trademarks = 1

Forward Citations = 26

Loading Chart...
Loading Chart...

22 inventors (with patents filed for the assignee):

goldMedal Nicolas Mermod (5 out of 9 patents)

silverMedal David Calabrese (4 out of 4 patents)

bronzeMedal Pierre Alain Girod (3 out of 3 patents)

4.  Philipp Bucher (3 out of 3 patents)

5.  Duc-Quang Nguyen (3 out of 3 patents)

6.  Stefania Puttini (3 out of 3 patents)

7.  Damien Saugy (3 out of 3 patents)

8.  Mermod Nicolas (1 out of 1 patent)

9.  Philippe Chatellard (1 out of 6 patents)

10.  Markus Imhof (1 out of 4 patents)

11.  Monique Zahn-Zabal (1 out of 1 patent)

12.  Pierre-Alain Girod (1 out of 1 patent)

13.  Sandra Bosshard (1 out of 2 patents)

14.  Pierre-Olivier Duroy (1 out of 2 patents)

15.  Philippe Le Mercier (1 out of 2 patents)


6 patents:

Company Overview
Selexis S.A. is a Swiss biotechnology company that specializes in mammalian cell-line generation. With its proprietary SUREtechnology Platform™, Selexis provides high-performance cell line development services to pharmaceutical and biotechnology companies worldwide. These cell lines enable the production of complex proteins such as monoclonal antibodies, fusion proteins, and enzymes for research and clinical applications.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#12 in Plan les Ouates

#1,481 in Switzerland

Plan les Ouates, CH
Plan les Ouates, Switzerland
Forward Citations = 26

22 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Selexis S.a.. Retrieved from https://idiyas.com/company/selexis-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…